Harwood Feffer LLP ( www.hfesq.com) is investigating potential claims against the board of directors of Inhibitex, Inc. (“Inhibitex” or the “Company”) (NASDAQ: INHX) concerning the proposed acquisition of the Company by Bristol-Myers Squib Co. (“Bristol-Myers”) in a transaction valued at approximately $2.5 billion. On January 7, 2012, Inhibitex announced that it had entered into a definitive agreement pursuant to which the Company will be acquired by Bristol-Myers. Under the terms of the agreement, Bristol-Myers will commence a tender offer that would pay holders of Inhibitex shares $26.00 per share in cash. Our investigation concerns whether the board of directors is fulfilling its fiduciary duties, maximizing the value of Inhibitex, disclosing all material benefits and costs and obtaining full and fair consideration for Inhibitex shareholders. If you own Inhibitex shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ( http://www.hfesq.com) for more information about the firm. Attorney Advertising. © 2012 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ( www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
|Robert I. Harwood, Esq.|
|Peter W. Overs, Jr., Esq.|
|Harwood Feffer LLP|
|488 Madison Avenue|
|New York, New York 10022|
|Phone Numbers:||(877) 935-7400|